Wyeth

Genetics Institute, Inc.

Marion T Kasaian

Debra D Donaldson

Lioudmila Tchistiakova

Samuel Goldman

Xiang-Yang Tan

Angela Widom

John L Knopf

Jose William Saldanha

Geertruida Machteld Veldman

Davinder Gill

Kimberly Ann Marquette

Lori J Fitz

Laura Lin

Eric Feyfant

Kevin Delos Parris

Tania Shane

Bruce Jacobson

Macy X Jin

Nancy L Wood

Amy Sze Pui Tam

Mary Collins

Glenn R Larsen

Matthew James Whitters

Beatriz M Carreno

Deborah A Young

Laura L Carter

Michelle J Unger

Joann Witek

Leslie D Lowe

Kyri Dunussi

Margery Ma

Joann S Witek

Michelle Ungar

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

Nucleic acids encoding IL-13 binding agents

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

IL-13 binding agents

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

Methods and compositions for modulating interleukin-21 receptor activity

Growing community of inventors

Charlestown, MA, United States of America

Marion T Kasaian